SBE has spearheaded and is involved with a number of consortia, including the CHO Consortium.
Shared Intellectual Property for Chinese Hamster Ovary (CHO) DNA Sequencing increases production efficiencies and drug development tools for life-saving medicines
Your company could benefit from membership in the CHO Consortium. View our latest press release, Society for Biological Engineering Consortium shares Genomic Sequences to improve Drug Development Efficiencies.
It’s a simple fact: about 70% of all biological products use the Chinese Hamster Ovary (CHO) cell line in their production. Yet compared to other mammals, the number of Chinese Hamster nucleotide sequences available in the genbank is small. For more details, read CHO Consortium on SBE Special Section, Recombinant Protein Therapeutics from CHO Cells – 20 Years and Counting.
Considerable work in identifying the balance of the CHO genome remains to be done. And in fact, significant progress has already been made—progress that your company can benefit from when you become a member of the CHO Consortium.
Consortium members pool their resources to support the ongoing work of oligonucleotide and genome sequencing. Each member company designates a representative to the Project Management Committee and helps guide upcoming research. In return, Consortium members receive periodic output of chips, access to annotated data through cDNA libraries, quarterly reports and biannual meetings. Sponsoring firms must be corporate members of the Society for Biological Engineering and abide by antitrust guidelines.
For more information on how your company can benefit from participation in the CHO Consortium and SBE Corporate membership, contact Darlene S. Schuster, Executive Director, at darls@aiche.org.
More information can also be found at http://hugroup.cems.umn.edu/CHO/cho_index.html.
